161 related articles for article (PubMed ID: 24506779)
1. Design and application of bispecific splice-switching oligonucleotides.
Bestas B; McClorey G; Tedebark U; Moreno PM; Roberts TC; Hammond SM; Smith CI; Wood MJ; Andaloussi SE
Nucleic Acid Ther; 2014 Feb; 24(1):13-24. PubMed ID: 24506779
[TBL] [Abstract][Full Text] [Related]
2. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
3. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
4. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.
Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R
Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856
[TBL] [Abstract][Full Text] [Related]
5. Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes.
Pires VB; Simões R; Mamchaoui K; Carvalho C; Carmo-Fonseca M
PLoS One; 2017; 12(7):e0181065. PubMed ID: 28742140
[TBL] [Abstract][Full Text] [Related]
6. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
[TBL] [Abstract][Full Text] [Related]
7. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy.
Kemaladewi DU; Hoogaars WM; van Heiningen SH; Terlouw S; de Gorter DJ; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; ten Dijke P; 't Hoen PA
BMC Med Genomics; 2011 Apr; 4():36. PubMed ID: 21507246
[TBL] [Abstract][Full Text] [Related]
8. Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice.
Lu-Nguyen NB; Jarmin SA; Saleh AF; Popplewell L; Gait MJ; Dickson G
Mol Ther; 2015 Aug; 23(8):1341-1348. PubMed ID: 25959011
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy.
Falzarano MS; Passarelli C; Ferlini A
Nucleic Acid Ther; 2014 Feb; 24(1):87-100. PubMed ID: 24506782
[TBL] [Abstract][Full Text] [Related]
10. Systemic Intravenous Administration of Antisense Therapeutics for Combinatorial Dystrophin and Myostatin Exon Splice Modulation.
Lu-Nguyen N; Dickson G; Malerba A
Methods Mol Biol; 2018; 1828():343-354. PubMed ID: 30171552
[TBL] [Abstract][Full Text] [Related]
11. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
12. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
[TBL] [Abstract][Full Text] [Related]
13. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.
Yin H; Betts C; Saleh AF; Ivanova GD; Lee H; Seow Y; Kim D; Gait MJ; Wood MJ
Mol Ther; 2010 Apr; 18(4):819-27. PubMed ID: 20068555
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
15. Screening for antisense modulation of dystrophin pre-mRNA splicing.
Dickson G; Hill V; Graham IR
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S67-70. PubMed ID: 12206799
[TBL] [Abstract][Full Text] [Related]
16. Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.
Wilton SD; Fletcher S
Curr Pharm Des; 2010; 16(8):988-1001. PubMed ID: 20041827
[TBL] [Abstract][Full Text] [Related]
17. Design and Application of a Short (16-mer) Locked Nucleic Acid Splice-Switching Oligonucleotide for Dystrophin Production in Duchenne Muscular Dystrophy Myotubes.
Carvalho C; Carmo-Fonseca M
Methods Mol Biol; 2020; 2161():37-50. PubMed ID: 32681504
[TBL] [Abstract][Full Text] [Related]
18. Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides.
Tone Y; Mamchaoui K; Tsoumpra MK; Hashimoto Y; Terada R; Maruyama R; Gait MJ; Arzumanov AA; McClorey G; Imamura M; Takeda S; Yokota T; Wood MJA; Mouly V; Aoki Y
Nucleic Acid Ther; 2021 Apr; 31(2):172-181. PubMed ID: 33567244
[TBL] [Abstract][Full Text] [Related]
19. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
